Encorafenib + Cetuximab With Chemo Improves Survival in Colon Cancer

作者
Mark L. Fuerst
出处
期刊:Oncology times [Wolters Kluwer]
卷期号:47 (10): 17-17
标识
DOI:10.1097/01.cot.0000000000000136
摘要

A combination of the BRAF inhibitor encorafenib and the EGFR inhibitor cetuximab with mFOLFOX6 chemotherapy improves survival in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC), according to results from an international Phase III clinical trial. In the BREAKWATER study of 637 participants, patients treated with encorafenib/cetuximab with mFOLFOX6 (folinic acid, fluorouracil, and oxaliplatin) had a 51% lower risk of dying than patients treated with standard-of-care chemotherapy with or without bevacizumab, and also had a 47% lower risk of cancer progression. “Encorafenib plus cetuximab plus mFOLFOX6 is a practice-changing, new standard of care for people with metastatic colorectal with a BRAFV600E mutation,” said lead author Elena Elez, MD, PhD, Head of the Colorectal Cancer Group at the Vall d'Hebron Institute of Oncology in Barcelona, Spain, at the 2025 ASCO Annual Meeting. Background BRAFV600E mutations occur in 8% to 12% of patients with mCRC. The disease carries a poor prognosis, and first-line standard-of-care chemotherapy has limited efficacy. Encorafenib is a highly selective, ATP-competitive inhibitor that combined with cetuximab was first approved in 2020 for BRAFV600E-mutant mCRC in second-line and later-line settings based on results from the BEACON study. BREAKWATER evaluated the targeted therapy combination with or without mFOLFOX6 vs. standard care in previously untreated BRAF V600E-mutant mCRC. Previously, BREAKWATER met one of its dual primary endpoints by demonstrating clinically meaningful and statistically significant improvement in confirmed overall response rate (ORR), and the FDA granted accelerated approval for encorafenib plus cetuximab and mFOLFOX6 in patients with BRAFV600E-mutant mCRC, including the first-line setting. Before BREAKWATER, there were no approved biomarker-driven therapies specifically indicated for patients with previously untreated BRAFV600E-mutant mCRC, Elez said. About the Study The BREAKWATER study originally included three treatment arms: encorafenib/cetuximab alone (158 patients), encorafenib/cetuximab with mFOLFOX6 (236 patients), and the control arm of chemotherapy with or without bevacizumab (243 patients). When early results showed that the encorafenib/cetuximab with mFOLFOX6 arm had a statistically significant improvement in ORR, enrollment in the encorafenib/cetuximab alone arm was closed in a protocol amendment. Newly reported results show overall survival (OS) was 30.3 months in the encorafenib/cetuximab with mFOLFOX6 arm, 19.5 months in the encorafenib/cetuximab alone arm, and 15.1 months in the control arm. Progression-free survival (PFS) was 12.8 months in the encorafenib/cetuximab plus mFOLFOX6 arm, 6.8 months in the encorafenib/cetuximab alone arm, and 7.1 months in the control arm. ORR was 65.7% in the encorafenib/cetuximab plus mFOLFOX6 arm, 45.6% in the encorafenib/cetuximab alone arm, and 37.4% in the control arm. The median duration of response was 13.9 months with the triplet combination vs. 10.8 months with standard of care. Most of the side effects from these treatments were manageable, Elez noted. Serious side effects caused by the treatments occurred in 30% of patients in the encorafenib/cetuximab-alone arm, 46% of the encorafenib/cetuximab with mFOLFOX6 arm, and 39% of the control arm. The most common side effects for the encorafenib/cetuximab with mFOLFOX6 treatment were nausea, anemia, and diarrhea. Researchers will continue to study the encorafenib/cetuximab combination with another chemotherapy regimen, FOLFIRI, which combines the common chemotherapy drugs folinic acid, fluorouracil, and irinotecan. “The BREAKWATER study has met both of its primary dual endpoints and the key secondary endpoint,” Elez noted. “PFS data demonstrated statistically significant and clinically meaningful improvement. This second interim analysis of OS also demonstrated statistically significant and clinically meaningful improvement. The safety data continued to show that encorafenib plus cetuximab plus mFOLFOX6 was generally tolerable, with a safety profile consistent with that known for each agent and no substantial increase in chemotherapy dose reduction or discontinuation vs. standard of care.” Joel Saltzman, MD, ASCO Expert in gastrointestinal cancers and Vice Chair of Regional Oncology at the Taussig Cancer Center in the Cleveland Clinic, commented, “This trial continues to move the needle forward to a more personalized approach to care based on the molecular and genetic characteristics of metastatic colon cancer. This trial establishes frontline encorafemib, cetuximab, and FOLFOX as the new standard of care for BRAFV600E-mutant metastatic colorectal cancer.” Mark L. Fuerst is a contributing writer.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
dyy123完成签到,获得积分10
1秒前
Fayth完成签到,获得积分0
1秒前
江边拔草完成签到,获得积分10
1秒前
七安发布了新的文献求助10
1秒前
学术智子发布了新的文献求助10
2秒前
李健的小迷弟的应助被Sweetx采纳,获得10
3秒前
3秒前
awang发布了新的文献求助20
4秒前
Tong完成签到,获得积分10
4秒前
4秒前
如意听安完成签到,获得积分10
4秒前
领导范儿的应助被再睡亿分钟采纳,获得10
5秒前
5秒前
6秒前
mmol完成签到,获得积分10
6秒前
huang完成签到,获得积分10
7秒前
xixi发布了新的文献求助10
7秒前
七安完成签到,获得积分20
8秒前
赘婿的应助被dyy123采纳,获得10
8秒前
8秒前
8秒前
yy发布了新的文献求助10
8秒前
大模型的应助被zzh采纳,获得10
8秒前
John_Xiong完成签到,获得积分10
9秒前
华圣拿下巨蜥完成签到,获得积分10
9秒前
9秒前
9秒前
无花果的应助被远方采纳,获得10
9秒前
9秒前
ws发布了新的文献求助10
9秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
10秒前
FashionBoy的应助被科研牛马采纳,获得10
11秒前
11秒前
希望天下0贩的0的应助被mmol采纳,获得10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182102
求助须知:如何正确求助?哪些是违规求助? 9571775
关于积分的说明 21819723
捐赠科研通 7778500
什么是DOI,文献DOI怎么找? 3433617
关于科研通互助平台的介绍 2557786
邀请新用户注册赠送积分活动 2479651